Capital Stock [Abstract] Capital stock DESCRIPTION OF BUSINESS LIQUIDITY AND CAPITAL RESOURCES Liquidity and Capital Resources [Text Block] LIQUIDITY AND CAPITAL RESOURCES This element may be used for the entire disclosure related to entity's liquidity and capital resources, which includes description of entity's revenue, stockholders' equity, including other comprehensive income, and cash and cash equivalents disclosure. LICENSE AGREEMENTS LICENSE AGREEMENTS License Agreements Disclosure [Text Block] The entire disclosure for all or part of the information related to license agreements. Document and Entity Information Unpaid Costs Associated with Under Written Public Offering Unpaid costs associated with underwritten public offering Represents the amount of unpaid costs associated with underwritten public offering in a noncash or partial noncash transaction. Proceeds from Issuance of Common Stock by Underwritten Public Offering Represents the proceeds, net of underwriters' discounts, commissions and offering expenses, from the issuance of stock through an underwritten public offering. Net proceeds from issuance of shares through an underwritten public offering Amendment Description Excess Consideration Paid Over Fair Value Excess consideration paid over fair value Amount of expenses charged against earnings during the period related to business combination, which is the excess of the cost of the acquired entity over the fair value assigned to assets acquired and liabilities assumed. Amendment Flag Issuance of Common Shares [Abstract] Issuance of common shares Stock Issued During Period Value, Common Shares and Warrants Registered direct offerings of common shares and warrants, net Value of common stock and warrants issued during the reporting period. Adjustments to Additional Paid in Capital Credit Equity Financing Facility Credit equity financing facility Increase in Additional Paid-in-Capital pursuant to credit equity financing facility under which entity could borrow funds. Further, convertible notes are subject to repurchase by entity at each holder's option. Stock Issued During Period, Common Shares and Warrants Registered direct offerings of common shares and warrants, net (in shares) Number of common shares and warrants issued during the reporting period. Stock Issued During Period Value, Warrants Exercised Warrant exercises - various Value stock issued during the period as a result of the exercise of warrants. Stock Issued During Period Shares, Warrants Exercised Warrant exercises - various (in shares) Number of shares of stock issued during the period as a result of the exercise of warrants. Noncash Investment Investment - non-cash The value of investments in noncash investing or financing activities. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation Basis of Presentation and Accounting Policies [Text Block] Repayments of Short Term Convertible Debt Cash paid for convertible note repayment The cash outflow from the conversion at maturity of a short-term debt instrument which was exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Current Fiscal Year End Date Document Period End Date SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Accounts Payable, Current Accounts payable Accrued Royalties, Current Due to licensor - Antares Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Stock option expense Adjustments to Additional Paid in Capital, Warrant Issued Stock warrant expense Assets, Current [Abstract] CURRENT ASSETS Assets [Abstract] ASSETS Assets, Current TOTAL CURRENT ASSETS Assets TOTAL ASSETS Basis of Accounting [Text Block] BASIS OF PRESENTATION ACQUISITION OF NET ASSETS OF CELL GENESYS Business Combination Disclosure [Text Block] ACQUISITION OF NET ASSETS OF CELL GENESYS Business Combination, Acquisition Related Costs Acquired in-process research and development Capital Expenditures Incurred but Not yet Paid Purchase of fixed assets on account, non-cash investing activity Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD Cash received in transaction Cash Acquired from Acquisition Class of Stock [Domain] COMMITMENTS AND CONTINGENCIES Commitments Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Common Stock Common Stock [Member] Common Stock Common Stock, Shares, Outstanding Capital stock, outstanding shares Common Stock, Shares, Issued Capital stock, issued shares Common Stock, Value, Outstanding Capital stock Class C Special Shares Common Class C [Member] RETIREMENT PLAN Convertible Notes Payable, Current Current portion of Convertible Senior Notes Convertible Notes Payable, Noncurrent Long-term convertible senior notes Cost and Equity Method Investments Disclosure [Text Block] INVESTMENTS Costs and Expenses [Abstract] EXPENSES Costs and Expenses Total expenses Debt Disclosure [Text Block] CONVERTIBLE SENIOR NOTES CONVERTIBLE SENIOR NOTES Deposits Assets, Noncurrent Deposits Depreciation, Depletion and Amortization Depreciation and amortization Description of New Accounting Pronouncements Not yet Adopted [Text Block] RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION Earnings Per Share, Diluted Diluted (in dollars per share) Earnings Per Share, Basic Basic (in dollars per share) BASIC AND DILUTED NET LOSS PER SHARE (in dollars per share) Earnings Per Share, Basic and Diluted Earnings Per Share [Text Block] BASIC AND DILUTED NET LOSS PER SHARE BASIC AND DILUTED NET LOSS PER SHARE NET LOSS PER SHARE Employee-related Liabilities, Current Accrued compensation Equity Component [Domain] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS Gain (Loss) on Sale of Property Plant Equipment Loss on disposal of fixed assets General and Administrative Expense General and administration Condensed Statements of Operations Income Tax Disclosure [Text Block] INCOME TAXES INCOME TAXES Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Increase (Decrease) in Operating Capital [Abstract] Changes in other assets and liabilities affecting cash flows from operations Increase (Decrease) in Other Receivables Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses, deposits and other assets Increase (Decrease) in Royalties Payable Due to licensor - Antares Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Interest Expense Interest expense Interest Paid Interest paid Investment Income, Net Interest income INVESTMENTS Issuance of Stock and Warrants for Services or Claims Stock warrant expense - noncash LEASE ARRANGEMENTS Leases of Lessee Disclosure [Text Block] LEASE ARRANGEMENTS Liabilities, Current TOTAL CURRENT LIABILITIES Liabilities, Current [Abstract] CURRENT LIABILITIES Liabilities TOTAL LIABILITIES Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY License Costs Licensing expense Licenses Revenue Licensing revenue Long-term Investments Investments Investment in Ceregene, Inc. accounted under cost method Nature of Operations [Text Block] DESCRIPTION OF BUSINESS Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash (used in) operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] CASH FLOWS (USED IN) OPERATING ACTIVITIES Net Cash Provided by (Used in) Continuing Operations NET (DECREASE) CASH AND CASH EQUIVALENTS Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash (used in) investing activities Net Income (Loss) Available to Common Stockholders, Basic NET LOSS Net loss Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] CASH FLOWS (USED IN) INVESTING ACTIVITIES RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Other assets acquired in Cell Genesys transaction Noncash or Part Noncash Acquisition, Other Assets Acquired Investment aquired through Cell Genesys transaction Noncash or Part Noncash Acquisition, Investments Acquired Noncash or Part Noncash Acquisition, Other Liabilities Assumed Accrued liabilities for deferred acquisition costs, noncash Liabilities acquired through Cell Genesys transaction Noncash or Part Noncash Acquisition, Value of Liabilities Assumed Nonoperating Income (Expense) [Abstract] OTHER BASIS OF PRESENTATION Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Other Noncash Income (Expense) Other non-cash items Other Receivables, Gross, Current Accounts receivable Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net Investment impairment charge Investment impairment charge Other Assets, Noncurrent [Abstract] OTHER ASSETS Other Nonoperating Income Other income Other Noncash Investing and Financing Items [Abstract] Noncash investing and financing activities Other Revenue, Net Other revenue Other Accrued Liabilities, Current Other accrued expenses Purchase of fixed assets Payments to Acquire Property, Plant, and Equipment Payments to Acquire Productive Assets Purchase of capital assets Payments to Acquire Short-term Investments Purchase of short term investments Pension and Other Postretirement Benefits Disclosure [Text Block] RETIREMENT PLAN Prepaid Expense and Other Assets, Current Prepaid expenses and other assets Proceeds from Warrant Exercises Proceeds from common stock warrant exercises Proceeds from (Payments for) Other Financing Activities Cash paid for transaction related costs Proceeds from Issuance of Common Stock Proceeds from issuance of common stock by registered direct offerings Proceeds from Sale of Productive Assets Proceeds from sale of fixed assets Proceeds from Sale of Short-term Investments Redemption of short term investments Proceeds from common stock option exercises Proceeds from Stock Options Exercised PROPERTY AND EQUIPMENT Property, Plant and Equipment, Net PROPERTY AND EQUIPMENT, NET Property, Plant and Equipment Disclosure [Text Block] PROPERTY AND EQUIPMENT Quarterly Financial Information [Text Block] SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) Research and Development Expense Research and development Acquired in-process research and development Research and Development in Process Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings [Member] Accumulated Deficit Revenue from Grants Grant revenue Revenues Total revenue Revenues [Abstract] REVENUE Royalty Revenue Royalty revenue Scenario, Unspecified [Domain] Senior Notes, Current Current portion of convertible senior notes Share-based Compensation Employee & director stock-based compensation Statement [Table] Scenario [Axis] Statement [Line Items] Statement Statements of Stockholders' Equity Condensed Statements of Cash Flows Equity Components [Axis] Condensed Balance Sheets Class of Stock [Axis] Stock Issued During Period, Shares, Period Increase (Decrease) Stock Issued During Period, Shares, Acquisitions Issuance of common shares pursuant to Cell Genesys, Inc. transaction (in shares) Stock Issued During Period, Value, Stock Options Exercised Stock option exercise Stock Issued During Period, Value, Acquisitions Issuance of common shares pursuant to Cell Genesys, Inc. transaction Stock Issued During Period, Value, New Issues Underwritten offering of common shares, net Stock Issued Shares issued for convertible senior notes and accrued interest Stock Issued During Period, Shares, New Issues Stock issued during period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options exercised (in shares) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] STOCKHOLDERS' EQUITY Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest TOTAL STOCKHOLDERS' EQUITY Stockholders' Equity Attributable to Parent [Abstract] STOCKHOLDERS' EQUITY Stockholders' Equity Attributable to Parent TOTAL STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY Stockholders' Equity, Period Increase (Decrease) Subsequent Events [Text Block] SUBSEQUENT EVENT SUBSEQUENT EVENT Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION Weighted Average Number of Shares Outstanding, Diluted [Abstract] WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING Weighted Average Number of Shares Outstanding, Basic Basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Diluted (in shares) Convertible note fair value adjustment Fair Value, Option, Changes in Fair Value, Gain (Loss) Convertible note fair value adjustment Fair value adjustment Number of Vaccines Granted with FDA Orphan Drug Designation Number of cancer vaccines that have been granted FDA orphan drug designation Represents the number of cancer vaccines developed by the entity which have been granted FDA orphan drug designation. Schedule of Liquidity and Capital Resources [Table] Represents details pertaining to liquidity position and availability of capital resources to the entity. Convertible Senior Notes 3.125 Percent due 2013 [Member] 2013 Notes Represents convertible senior notes bearing an interest of 3.125 percent which mature in 2013. Liquidity and Capital Resources [Line Items] Liquidity and capital resources Proceeds from Issuance or Sale of Equity Net proceeds from issuance of shares and warrants Stock Issued During Period, Shares, Conversion of Convertible Securities Number of shares issued in exchange for cancellation for debt Number of shares issued in exchange for cancellation Number of Debt Instrument, Holders to Whom Shares are Issued Number of holders of debt instrument to whom shares are issued by the entity Represents the number of holders of debt instrument to whom shares are issued by the entity. Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Stock Options [Member] Stock options Warrant [Member] Warrants Convertible Debt Securities [Member] Convertible debt Minimum [Member] Low end of range Minimum Maximum [Member] High end of range Maximum Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Securities excluded from computation of earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of shares excluded from computation of EPS Antidilutive Securities Excluded from Computation of Earnings Per Share, Exercise Price of Securities Exercise price of securities (in dollars per share) Represents the exercise price of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future, that were not included in the computation of diluted EPS or EPU as it would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Debt Instrument, Face Amount Principal amount Debt Instrument, Convertible, Conversion Price Conversion price (in dollars per share) Right of Entity to Designate Members on Board of Investee Number of Members Number of members that the entity can designate on board of directors of Ceregene, Inc. Represents the number of members that can be designated on board of directors of the investee by virtue of their stock ownership in that entity. Schedule of Fair Value Assumptions Used for Debt Instruments [Table Text Block] Schedule of key assumptions used to establish the value of the 2013 Notes Tabular disclosure of the significant assumptions used during the period to estimate the fair value of debt instruments. Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of maturities of required principal payments by year related to the convertible senior notes Convertible Senior Notes 3.125 Percent Due 2011 [Member] 2011 Notes Represents convertible senior notes bearing an interest of 3.125 percent which mature in 2011. Debt Instrument [Line Items] Convertible senior notes Number of Series of Convertible Notes Assumed Number of series of convertible notes assumed in merger Represents the number of series of convertible notes assumed by the entity. Debt Instrument, Convertible, Number of Equity Instruments Number of shares of common stock receivable upon conversion Long Term Debt, Redemption Price as Percentage of Principal Amount, Option to Holder Percentage of principal amount at which the holder may require the entity to repurchase notes Represents the percentage of principal amount used in the computation of the redemption price at which the holders may require the entity to repurchase the debt instruments on or after specified dates in case a fundamental change (as defined in the indenture) occurs. Long Term Debt, Redemption Price as Percentage of Principal Amount Percentage of principal amount at which the entity may redeem notes in whole or in part Represents the percentage of principal amount used in the computation of the redemption price at which the entity may redeem some or all of the debt instruments on or after specified dates. Debt Instrument Conversion Obligation Common Stock Closing Sales Price as Percentage of Conversion Price Percentage of the closing sales price of the entity's common stock that the conversion price must exceed in order for the notes to be convertible Represents the percentage of the closing sales price of the entity's common stock for at least 20 days within 30 consecutive trading days that the closing sales price of the entity's common stock must exceed the conversion price in order for the debt instruments to be convertible. Debt Instrument Conversion Obligation Common Stock Closing Sales Price Number of Trading Days Number of days within 30 consecutive trading days in which the closing price of the entity's common stock must exceed the conversion price for the notes to be redeemable (in days) Represents the number of trading days within a period of 30 consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price in order for the debt instruments to be convertible. Debt Instrument Conversion Obligation Number of Consecutive Trading Days Number of consecutive trading days during which the closing price of the entity's common stock must exceed the conversion price for at least 20 days in order for the notes to be redeemable (in days) Represents the number of consecutive trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the debt instruments to be convertible. Long-term Debt, Fair Value Recorded fair value Fair Value, Option, Aggregate Differences, Long-term Debt Instruments Amount of difference between aggregate recorded fair value of the notes and their total stated principal amount Fair Value Assumptions and Methodology for Assets and Liabilities [Abstract] Assumptions to establish the value of the Notes Fair Value Assumptions, Risk Free Interest Rate Average risk-free rate (as a percent) Fair Value Assumptions, Expected Volatility Rate Volatility of BioSante common stock (as a percent) Fair Value Assumptions Discount Rate Discount rate for principal payments in cash (as a percent) Represents discount rate for principal payments in cash, an assumption used in valuation of an instrument. Long-term Debt, Fiscal Year Maturity [Abstract] Maturities of required principal payments by year Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year 2012 Long-term Debt, Maturities, Repayments of Principal in Year Two 2013 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Authorized before Amendment Number of shares of the entity's common stock authorized for issuance under the plan before amendment The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), before amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested). Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Number of shares of the entity's common stock authorized for issuance under the plan Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of shares that remained available for issuance under the plan Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options granted under the plan (in shares) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price of options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Options expired and cancelled (in shares) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average exercise price of options exercised (in dollars per share) Share Based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Expirations in Period Warrants expired (in shares) Represents the decrease in the number of shares that could be issued, attributable to the lapse of rights to exercise previously issued awards other than stock options under the terms of the award agreements under the plan during the reporting period. Share Based Compensation Arrangement by Share Based Payment Award Other than Options Expired in Period, Weighted Average Exercise Price Weighted average exercise price of warrants expired (in dollars per share) Represents the weighted average price at which grantees could have exercised the awards that were terminated during the reporting period due to noncompliance with plan terms during the reporting period. Schedule of Stockholders Equity [Table] Represents information pertaining to changes in stockholder's equity. Warrant Issued to Institutional Investors [Member] Warrants issued to institutional investors Represents details pertaining to warrants, which are issued to institutional investors. Warrant Issued to Placement Agents [Member] Placement agent warrants Represents details pertaining to warrants, which are issued to placement agents. Stockholders Equity [Line Items] Stockholder's equity Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued (in shares) Share Price Purchase price (in dollars per share) Proceeds from Issuance of Common Stock, Gross Gross proceeds from issuance of shares Represents the gross amount of cash inflow from the additional capital contribution to the entity. Class of Warrant or Right Term of Warrants Term of warrants (in years) Represents the term over which the warrants expire. Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price (in dollars per share) Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of financial assets and liabilities recorded at fair value on a recurring basis Fair Value, Measurements, Recurring [Member] Recurring basis Estimate of Fair Value, Fair Value Disclosure [Member] Total Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 3 [Member] Significant Other Unobservable Inputs (Level 3) Money Market Funds [Member] Money market fund Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair value of assets and liabilities Assets, Fair Value Disclosure [Abstract] Assets: Assets, Fair Value Disclosure Total Assets Liabilities, Fair Value Disclosure [Abstract] Liabilities: Convertible Debt, Fair Value Disclosures Fair value of convertible debt Liabilities, Fair Value Disclosure Total liabilities Long-term Debt Total Convertible Notes Payable [Member] 2013 Notes Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Asset Class [Axis] Fair Value by Asset Class [Domain] Liability Class [Axis] Fair Value by Liability Class [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Schedule of Long-term Debt Instruments [Table] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Range [Axis] Range [Domain] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Domain] Interest income Investment Income, Interest Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash (used in) operations Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Payments to Acquire Investments Purchase of investment Payments to Fractional Share Payout Fractional share payout Represents payments of fractional shares as a result of reverse stock split. Stockholders Equity Reverse, Stock Split Conversion Ratio Reverse stock split conversion ratio Represents the conversion ratio used in the calculation of reverse stock split. Number of Products or Technologies Licensed by Entity as Alternative to Raising Additional Financing Number of products or technologies licensed by the entity as an alternative to raising additional financing Represents the number of products or technologies licensed by the entity as an alternative to raising additional financing. Fair Value, Option, Credit Risk, Gains (Losses) on Liabilities Fair value adjustment attributable to the change in instrument specific credit risk Aptar Pharma [Member] Aptar Pharma Represents the details pertaining to Aptar Pharma. Capital Addition Purchase Commitments [Member] Gel Packaging Machine Long-term Purchase Commitment [Line Items] Commitment and contingencies Purchase Commitment Cumulative Payments to Acquire Machinery Amount paid Represents the cumulative amount paid by the entity for purchase of machinery. Long-term Purchase Commitment, Amount Amount of commitment to purchase machinery Purchase Obligation Remaining obligation Legal Entity [Axis] Entity [Domain] Long-term Purchase Commitment [Table] Category of Item Purchased [Axis] Long-term Purchase Commitment, Category of Item Purchased [Domain] Number of Phase I and Phase II Clinical Trials Number of Phase I and Phase II clinical trials Represents the number of Phase I and Phase II clinical trials for the treatment of various cancers in which the entity is participating. Accrued and unpaid interest payable on cancellation of debt Interest Payable Number of New LibiGel Phase III Efficacy Trials Number of new LibiGel Phase III efficacy trials Represents the number of new LibiGel Phase III efficacy trials. Fair Value Option Changes in Fair Value NonCash Adjustment Additional non-cash fair value adjustment attributable to conversion of debt For each line item in the statement of financial position, the non-cash increase (decrease) in fair value resulting from transactions during the period. Debt Conversion, Original Debt, Amount Principal amount of debt cancelled